4basebio (XTER:88Q) Capex-to-Operating-Income : 0.00 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is 4basebio Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

4basebio's Capital Expenditure for the six months ended in Jun. 2023 was €-0.86 Mil. Its Operating Income for the six months ended in Jun. 2023 was €-4.39 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

4basebio Capex-to-Operating-Income Historical Data

The historical data trend for 4basebio's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Capex-to-Operating-Income Chart

4basebio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Capex-to-Operating-Income

4basebio Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Capex-to-Operating-Income	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of 4basebio's Capex-to-Operating-Income

For the Biotechnology subindustry, 4basebio's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4basebio's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4basebio's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where 4basebio's Capex-to-Operating-Income falls into.

4basebio Capex-to-Operating-Income Calculation

4basebio's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-2.232)	/	-6.715
	=	N/A

4basebio's Capex-to-Operating-Income for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.858)	/	-4.387
	=	N/A

4basebio (XTER:88Q) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

4basebio Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of 4basebio's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

4basebio (XTER:88Q) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (XTER:88Q) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

4BB:UK

Address

25 Norman Way, Over, Cambridge, GBR, CB24 5QE

Website

https://www.4basebio.com

4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (XTER:88Q) Headlines

No Headlines